Petroski Jason, Strachan Kelly, Schluterman Nicholas, Doss William
Division of Drug Innovation, Centers for Medicare and Medicaid Services, CMS Innovation Center, Baltimore, MD 21244, United States.
Centers for Medicare and Medicaid Services, CMS Innovation Center, Baltimore, MD 21244, United States.
Health Aff Sch. 2024 Nov 19;2(12):qxae152. doi: 10.1093/haschl/qxae152. eCollection 2024 Dec.
Significant research and attention to date have focused on cost-related medication nonadherence as rising prescription drug prices worsen affordability and access for many Americans. This study investigated self-reported sources of medication nonadherence, measuring both cost- and non-cost-related medication nonadherence among community-dwelling Medicare Part D beneficiaries in 2022. A total of 13.7% of beneficiaries (4 589 843) reported some type of medication nonadherence; 7.5% reported medication nonadherence related to cost and 6.2% reported for non-cost reasons. Beneficiaries reporting food insecurity, poor functional status, and lack of understanding of the Part D benefit were more likely to report both types of medication nonadherence after adjustment for sociodemographic factors. Beneficiaries receiving the Low-Income Subsidy had lower odds of reporting cost-related but greater odds of reporting non-cost-related medication nonadherence. These findings suggest that non-cost-related sources of medication nonadherence, such as beneficiary preferences or beliefs, understanding of their health situation or insurance coverage, and ability to fill a prescription, are significant contributors to overall nonadherence. Non-cost-related medication nonadherence should be considered alongside recent changes to the Part D benefit and in future Part D Centers for Medicare and Medicaid Services (CMS) Innovation Center models, such as the proposed Medicare $2 Drug List Model, in order to maximize the impact of these initiatives.
由于处方药价格不断上涨,许多美国人的支付能力和可及性受到影响,因此迄今为止,大量研究和关注都集中在与成本相关的药物治疗不依从性上。本研究调查了自我报告的药物治疗不依从性来源,测量了2022年社区居住的医疗保险D部分受益人中与成本相关和与非成本相关的药物治疗不依从性情况。共有13.7%的受益人(4589843人)报告了某种类型的药物治疗不依从性;7.5%报告了与成本相关的药物治疗不依从性,6.2%报告了非成本原因导致的不依从性。在对社会人口因素进行调整后,报告粮食不安全、功能状态差以及对D部分福利缺乏了解的受益人更有可能报告这两种类型的药物治疗不依从性。接受低收入补贴的受益人报告与成本相关的药物治疗不依从性的几率较低,但报告非成本相关的药物治疗不依从性的几率较高。这些发现表明,与成本无关的药物治疗不依从性来源,如受益人的偏好或信念、对自身健康状况或保险覆盖范围的理解以及开具处方的能力,是总体不依从性的重要因素。在考虑D部分福利的近期变化以及未来医疗保险和医疗补助服务中心(CMS)创新中心的模式(如拟议的医疗保险2美元药品清单模式)时,应考虑与成本无关的药物治疗不依从性,以便最大限度地发挥这些举措的影响。